These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36781338)

  • 1. Re: Ithaar H. Derweesh, Rana R. McKay, Aditya Bagrodia. Primary Cytoreductive Nephrectomy: Standing the Test of Time? Eur Urol. 2023;83:152-3.
    Mejean A
    Eur Urol; 2023 May; 83(5):e135. PubMed ID: 36781338
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606-17.
    Marconi L; MacLennan S; Lam TBL; Canfield SE; Yuan Y; Omar MI; N'Dow J; Sylvester R
    Eur Urol; 2017 Sep; 72(3):e59-e60. PubMed ID: 28629586
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606-17.
    Kim JH; Chung BI
    Eur Urol; 2017 Nov; 72(5):e127-e128. PubMed ID: 28545840
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
    Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
    Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
    Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
    Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
    Ghoreifi A; Djaladat H
    Eur Urol; 2023 Aug; 84(2):e53-e54. PubMed ID: 37149463
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.
    Li J; Chen B; Cao D
    Eur Urol; 2023 Sep; 84(3):e75. PubMed ID: 37270390
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606-17.
    Mir MC; Derweesh IH; Autorino R
    Eur Urol; 2017 Nov; 72(5):e129-e130. PubMed ID: 28528815
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Lorenzo Marconi, Steven MacLennan, Thomas B.L. Lam, et al's Letter to the Editor re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606-17.
    Derweesh IH; Mir MC; Autorino R
    Eur Urol; 2017 Sep; 72(3):e61-e62. PubMed ID: 28642021
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? No, cytoreductive nephrectomy should no longer be routinely performed.
    Kim HL
    Curr Opin Urol; 2020 Sep; 30(5):743-745. PubMed ID: 32732627
    [No Abstract]   [Full Text] [Related]  

  • 12. Primary Cytoreductive Nephrectomy: Standing the Test of Time?
    Derweesh IH; McKay RR; Bagrodia A
    Eur Urol; 2023 Feb; 83(2):152-153. PubMed ID: 36372629
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytoreductive nephrectomy is dead, long live cytoreductive nephrectomy.
    Capitanio U; Larcher A; Montorsi F
    BJU Int; 2019 Jul; 124(1):6-7. PubMed ID: 30656818
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytoreductive nephrectomy for favorable risk patients with metastatic renal cell carcinoma? Yes, cytoreductive nephrectomy should still be considered.
    Meza L; Chehrazi-Raffle A; Pal SK
    Curr Opin Urol; 2020 Sep; 30(5):740-742. PubMed ID: 32732626
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytoreductive Nephrectomy for Synchronous Metastatic Renal Cell Carcinoma-Are There Any Favorable Risk Patients?
    Patel HD; Clark JI; Flanigan RC
    J Urol; 2021 Jul; 206(1):4-6. PubMed ID: 33560871
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular Extraction of Caval Tumor Thrombus to Facilitate Minimally Invasive Cytoreductive Nephrectomy for Metastatic Kidney Cancer. Eur Urol 2015;68:167-8.
    Greco M; Butticè S; Magno C; Onida S
    Eur Urol; 2016 Aug; 70(2):e51-2. PubMed ID: 26850971
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus.
    Matveev VB; Volkova MI
    Eur Urol; 2017 Dec; 72(6):1024. PubMed ID: 28916409
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.
    Laguna MP
    J Urol; 2016 Jul; 196(1):57-9. PubMed ID: 27321494
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: The evolving role of cytoreductive nephrectomy.
    Singla N; Hakimi AA; Margulis V
    Curr Opin Urol; 2019 Sep; 29(5):505-506. PubMed ID: 31246591
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?
    Massari F; Di Nunno V; Santoni M
    Eur Urol Oncol; 2019 May; 2(3):340-341. PubMed ID: 31200852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.